Photograph: Christopher Occhicone/Bloomberg

Drugmaker Merck said on Thursday Kenneth Frazier, one of only a handful of black executives leading major US companies, will step down as chief execu(...)

Merck this year bought Austrian vaccine maker Themis Bioscience to gain its vaccine project that relies on a measles vector.

Merck aims to start human trials on one of its Covid-19 vaccine candidates “fairly soon,” with a second vaccine candidate likely to begin trials later(...)

Merck’s cancer drug Keytruda booked sales of more than $2 billion for the first time in the fourth quarter. Photograph: Brendan McDermid/Reuters

Merck’s cancer immumotherapy Keytruda booked sales of more than $2 billion in a quarter for the first time, exceeding Wall Street’s lofty estimates an(...)

Merck’s total sales rose 5.4 per cent to $10.47 billion but  investors  expected bigger gains in market share for the cancer therapy. Photograph: Ralph Orlowski/Reuters

Merck & Co beat quarterly profit estimates on Friday as sales of its blockbuster drug Keytruda overtook rival Bristol-Myers Squibb’s Opdivo, but t(...)

US president Donald Trump: Many business leaders remain on his advisory panels and councils. These include Dell’s Michael Dell, Apple’s Tim Cook, IBM’s Ginny Rometty, Corning’s Wendell Weeks and GE’s Jeff Immelt. Photograph: Jim Watson/AFP/Getty

Since its arrival a decade ago, I’d wager Twitter has proven overall to be more of a thorn than a rose for most companies.  As a public-facing p(...)

A photograph taken on February 23rd, 2017, showing President Trump and Merck CEO Kenneth Frazier during a meeting with manufacturing CEOs in the White House. Photograph: Getty Imagescc

The resignation of Merck chief executive Kenneth Frazier from one of US president Donald Trump’s business panels has highlighted the growing tendency (...)

A worker  outside a Merck facility in  New Jersey, US, yesterday.  The  drugmaker  will eliminate  8,500 of its 81,000 global workforce  in its latest revamp. Photograph: Emile Wamsteker/Bloomberg

Merck, taking a cue from rival drugmakers that have slashed research spending to bolster earnings, has said it plans to cut annual operating costs by(...)